Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma

Jazz Pharmaceuticals and EUSA Pharma announced that the companies have signed a definitive agreement under which Jazz has agreed to acquire EUSA for $650 million in cash and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze (asparaginase Erwinia chrysanthemi).
The Sacramento Bee